Thursday November 5, 2026
41° Grand Junction, CO Mostly Cloudy
Become a Contributor
Section

Press Releases

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease
Press Release

T-Therapeutics announces oversubscribed $133 million Series B financing to achieve clinical proof-of-concept for first-in-class TCR bispecific therapies in cancer and autoimmune disease

$133 million Series B financing co-led by new investors Advent Life Sciences and British Business Bank, with

Read Full Story